文献速递免疫规划妇幼与学校卫生

接种卡介苗的3月龄以下婴儿中医院治疗感染发生率较低

Lower incidence of hospital-treated infections in infants under 3 months of age vaccinated with BCG.
PubMed 文献 · Vaccine · 2022-09-09

芬兰2006年9月1日国家疫苗接种规划改变(此前所有新生儿接种卡介苗,此后仅高危组接种),研究者采用前后对照设计,比较2004年7月1日至2006年6月30日出生(卡介苗可接种)与2007年7月1日至2009年6月30日出生(卡介苗不可接种)的足月儿。卡介苗可接种队列(N=93,658)相比不可接种队列(N=94,712)在3月龄随访期内医院诊断感染的发生率比为0.89(95%CI 0.86-0.93),下降主要由呼吸道感染引起;4-12月龄随访期卡介苗可接种组感染略多(IRR 1.03,95%CI 1.01-1.06)。结论认为卡介苗接种与生命最初三个月内所有医院诊断感染发生率较低相关。

要点

  • 卡介苗可接种队列3月龄内医院诊断感染IRR为0.89(95%CI 0.86-0.93),低于不可接种队列。
  • 感染下降主要由呼吸道感染引起。
  • 4-12月龄随访期卡介苗可接种组感染略多,IRR 1.03(95%CI 1.01-1.06)。

核心结论

  • 卡介苗接种与生命最初三个月内所有医院诊断感染发生率较低相关。
  • 该差异不能归因于肺结核,因为2000年代芬兰仅出现少数儿科病例。
  • 灭活疫苗接種后非特异性效应消失,这与既往研究相符。

研究设计与样本

  • 利用芬兰国家疫苗接种规划2006年9月1日改变(此前所有新生儿接种卡介苗,此后仅高危组婴儿接种)开展自然实验,采用前后对照设计。
  • 比较2004年7月1日至2006年6月30日出生(卡介苗可接种,N=93,658)与2007年7月1日至2009年6月30日出生(卡介苗不可接种,N=94,712)的年龄和季节匹配参照队列,使用泊松回归分析。
  • 队列限制为父母出生于芬兰的足月儿,随访从出生开始持续3个月(计划DTaP-IPV-Hib接种年龄),并从4月龄至满1岁。
  • 结局包括所有感染、肺炎和作为阴性对照结局的损伤,数据来自芬兰健康登记。

主要发现

  • 3月龄随访期内,卡介苗可接种队列(N=93,658)相比卡介苗不可接种队列(N=94,712)医院诊断感染的发生率比为0.89(95%CI 0.86-0.93)。
  • 感染下降主要由呼吸道感染引起。
  • 4-12月龄随访期内,卡介苗可接种组感染略多于卡介苗不可接种组,IRR为1.03(95%CI 1.01-1.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Live vaccines potentially have non-specific effects that protect against other infections than those the vaccines are targeted against. The national vaccination program (NVP) in Finland was changed on September 1st, 2006: before BCG vaccine was given to all newborn babies and afterwards to babies in risk groups only. We used this natural experiment to study the non-specific effects of BCG in the frame of NVP using before-after design. METHODS: We compared the incidence of several outcomes obtained from Finnish health registers between children born between July 1st, 2004, and June 30th, 2006 (BCG-eligible) and an age- and season-matched reference cohort born between July 1st, 2007, and June 30th, 2009 (BCG-non-eligible) using Poisson regression. These cohorts were restricted to full-term children whose parents were born in Finland. Follow-up began at birth and lasted 3 months, which is the scheduled age for DTaP-IPV-Hib vaccination, and from 4 months until first birthday. The outcomes included all infections, pneumonia and injuries as a negative control outcome. RESULTS: The incidence rate ratio (IRR) of the BCG-eligible cohort (N = 93,658) compared to BCG-non-eligible cohort (N = 94,712) for hospital-diagnosed infections was 0.89 (95 %Cl 0.86-0.93) for the 3-month follow-up. The decrease was mainly caused by respiratory infections. In 4-12 months follow-up the BCG-eligible had slightly more infections than BCG-non-eligible children (IRR 1.03, 1.01-1.06). CONCLUSIONS: BCG vaccination was associated with a lower incidence of all hospital-diagnosed infections during the first three months of life. The difference cannot be attributed to lung tuberculosis, since only few paediatric cases occurred in Finland during 2000s. The disappearance of non-specific effect after administration of an inactivated vaccine is compatible with previous studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nieminen H, Lahdenkari M, Syrjänen RK, et al. Lower incidence of hospital-treated infections in infants under 3 months of age vaccinated with BCG. Vaccine. 2022. PMID: 36096971. doi:10.1016/j.vaccine.2022.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。